Expert Answers in HER2+ Gastroesophageal Adenocarcinoma – with Dr. Manish Shah
A diagnosis of HER2+ gastroesophageal adenocarcinoma (GEA) can be overwhelming, bringing with it uncertainty, new medical terminology, and many questions about treatment options. Hear a perspective from gastrointestinal oncologist Dr. Manish Shah.
“You’re learning about biomarkers and how important they are.”
Understanding a HER2+ GEA Diagnosis
As part of our Expert Answers in HER2+ Gastroesophageal Adenocarcinoma series, leading specialists share practical insights to help patients and caregivers better understand the disease and navigate conversations with their healthcare team.
In this installment, Dr. Manish Shah, Gastrointestinal Oncologist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses:
- What patients should know when they are first diagnosed with HER2+ GEA
- The importance of biomarker testing
- Why there is growing optimism for the future
Explore more Expert Answers in HER2+ Gastroesophageal Adenocarcinoma:
- Yelena Janjigian, MD, Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center
- Jaffer A. Ajani, MD, Gastrointestinal Oncologist at MD Anderson Cancer Center
